EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab

Sohrab Elahwiesy, Franziska Jochims, Manfred Kunz, Susann Forkel, Jan‐Christoph Simon, Benjamin Klein

JEADV Clinical Practice · 12.06.2026

DOI: 10.1002/jvc2.70386 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JEADV Clinical Practice, online erschienen am 12.06.2026. Verfasst von Sohrab Elahwiesy und 5 weiteren Autor:innen. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lichen amyloidosis (LA) is a chronic, pruritic dermatosis with papillary dermal amyloid deposition. Standard therapies often fail, and most reports of dupilumab in LA involve patients with concomitant atopic dermatitis. We report a 32‐year‐old man with refractory, non‐atopic LA who had failed topical corticosteroids, tacrolimus, phototherapy, and acitretin. After 6 months of dupilumab, near‐complete resolution of pruritus and major improvement of skin lesions were achieved. Repeat biopsy demonstrated marked reduction of CD4+ and CD8 + T‐cell infiltrates and complete amyloid clearance, with residual postinflammatory hyperpigmentation. These findings support a direct therapeutic effect of dupilumab in non‐atopic LA and a central role for type 2 inflammation in disease pathogenesis.

Zitieren

APA

Elahwiesy, S., Jochims, F., Kunz, M., Forkel, S., Simon, J., & Klein, B. (2026). Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab. JEADV Clinical Practice. https://doi.org/10.1002/jvc2.70386

Vancouver

Elahwiesy S, Jochims F, Kunz M, Forkel S, Simon J, Klein B. Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab. JEADV Clinical Practice. 2026. doi:10.1002/jvc2.70386

BibTeX
@article{Elahwiesy2026,
  author = {Elahwiesy, Sohrab and Jochims, Franziska and Kunz, Manfred and Forkel, Susann and Simon, Jan‐Christoph and Klein, Benjamin},
  title = {Successful Treatment of Refractory Lichen Amyloidosus With Dupilumab},
  journal = {JEADV Clinical Practice},
  year = {2026},
  doi = {10.1002/jvc2.70386}
}
Kostenlos starten →